Moxibustion treatment restoring the intestinal epithelium barrier in rats with Crohn’s disease by down-regulating tumor necrosis factor alpha, tumor necrosis factor receptor 1, and tumor necrosis factor receptor 2

Yin Shi; En-hua Zhou; Huan-gan Wu; Ci-li Zhou; Qian-yao Wang; Li Qi

doi:10.1007/s11655-011-0669-3

Your Location：

Home >

Browse articles >

Moxibustion treatment restoring the intestinal epithelium barrier in rats with Crohn’s disease by down-regulating tumor necrosis factor alpha, tumor necrosis factor receptor 1, and tumor necrosis factor receptor 2

OriginalPaper | Updated：2021-08-27

- Moxibustion treatment restoring the intestinal epithelium barrier in rats with Crohn’s disease by down-regulating tumor necrosis factor alpha, tumor necrosis factor receptor 1, and tumor necrosis factor receptor 2
- Moxibustion treatment restoring the intestinal epithelium barrier in rats with Crohn’s disease by down-regulating tumor necrosis factor alpha, tumor necrosis factor receptor 1, and tumor necrosis factor receptor 2
- 中国结合医学杂志（英文版） 2011年17卷第3期页码：212-217
- Affiliations：
  
  1. Shanghai Institute of Acupuncture-Moxibustion and Meridians, Shanghai University of Traditional Chinese Medicine,Shanghai,China
  2. Department of Mechanics and Engineering Science, Fudan University,Shanghai,China
- Author bio：
- Funds：
  
  Supported by National Basic Research Program of China (973 Program, No. 2009CB522900), National Natural Science Foundation of China (No. 30772831), and the Open Fund of Key Laboratory of Acupuncture Combined with Medication (Najing University of Traditional Chinese Medicine), Ministry of Education (Grant No. KJA200809)
- DOI：10.1007/s11655-011-0669-3
  中图分类号：
- 纸质出版日期：2011，
  
  网络出版日期：2011-2-27，
Scan for full text
Shi, Y., Zhou, Eh., Wu, Hg. et al. Moxibustion treatment restoring the intestinal epithelium barrier in rats with Crohn’s disease by down-regulating tumor necrosis factor alpha, tumor necrosis factor receptor 1, and tumor necrosis factor receptor 2., Chin. J. Integr. Med. 17, 212–217 (2011). https://doi.org/10.1007/s11655-011-0669-3

Yin Shi, En-hua Zhou, Huan-gan Wu, et al. Moxibustion treatment restoring the intestinal epithelium barrier in rats with Crohn’s disease by down-regulating tumor necrosis factor alpha, tumor necrosis factor receptor 1, and tumor necrosis factor receptor 2[J]. Chinese Journal of Integrative Medicine, 2011,17(3):212-217.
Shi, Y., Zhou, Eh., Wu, Hg. et al. Moxibustion treatment restoring the intestinal epithelium barrier in rats with Crohn’s disease by down-regulating tumor necrosis factor alpha, tumor necrosis factor receptor 1, and tumor necrosis factor receptor 2., Chin. J. Integr. Med. 17, 212–217 (2011). https://doi.org/10.1007/s11655-011-0669-3 DOI：

Yin Shi, En-hua Zhou, Huan-gan Wu, et al. Moxibustion treatment restoring the intestinal epithelium barrier in rats with Crohn’s disease by down-regulating tumor necrosis factor alpha, tumor necrosis factor receptor 1, and tumor necrosis factor receptor 2[J]. Chinese Journal of Integrative Medicine, 2011,17(3):212-217. DOI： 10.1007/s11655-011-0669-3.

摘要

To investigate whether moxibustion regulates tumor necrosis factor alpha (TNF-α)

tumor necrosis factor receptor 1 (TNFR1)

and TNFR2 in the intestinal mucosa and to explore whether moxibustion could be used by means of this mechanism

to repair the intestinal epithelium barrier disruption in Crohn’s disease (CD). The CD rat models were established by trinitrobenzene sulfonic acid (TNBs)

randomly divided into a model control (MC) group

an herb-partition moxibustion (HPM) group

a mild-warm moxibustion (MWM) group

and a salicylazosulfapyridine (SASP) group

and all were compared with a normal control (NC) group. The HPM and MWM groups were treated by moxibustion at Tianshu (ST25) and Qihai (RN6) for 14 days

and the SASP group obtained the SASP solution orally for the same period of time. The intestinal epithelium morphology and TNF-α

TNFR1

and TNFR2 contents were observed by the transmission electron microscopy and enzyme linked immunosorbent assay. The severity of morphological changes in CD intestinal epithelium was obviously improved

and the levels of TNF-α

TNFR1

and TNFR2 in the intestinal mucosa all significantly decreased in the HPM and MWM groups. However

there were no significant differences between the HPM and MWM groups. The moxibustion therapies (HPM and MWM) could reduce intestinal inflammation and restore intestinal epithelium barrier disruption in CD

which might be due to down-regulating TNF-α

TNFR1

and TNFR2 in intestinal mucosa and improving intestinal epithelium morphology.

Abstract

To investigate whether moxibustion regulates tumor necrosis factor alpha (TNF-α)

tumor necrosis factor receptor 1 (TNFR1)

and TNFR2 in the intestinal mucosa and to explore whether moxibustion could be used by means of this mechanism

to repair the intestinal epithelium barrier disruption in Crohn’s disease (CD). The CD rat models were established by trinitrobenzene sulfonic acid (TNBs)

randomly divided into a model control (MC) group

an herb-partition moxibustion (HPM) group

a mild-warm moxibustion (MWM) group

and a salicylazosulfapyridine (SASP) group

and all were compared with a normal control (NC) group. The HPM and MWM groups were treated by moxibustion at Tianshu (ST25) and Qihai (RN6) for 14 days

and the SASP group obtained the SASP solution orally for the same period of time. The intestinal epithelium morphology and TNF-α

TNFR1

and the levels of TNF-α

TNFR1

and TNFR2 in the intestinal mucosa all significantly decreased in the HPM and MWM groups. However

which might be due to down-regulating TNF-α

TNFR1

and TNFR2 in intestinal mucosa and improving intestinal epithelium morphology.

关键词

moxibustionCrohn’s diseasetumor necrosis factor alphatumor necrosis factor receptor 1tumor necrosis factor receptor 2

Keywords

moxibustionCrohn’s diseasetumor necrosis factor alphatumor necrosis factor receptor 1tumor necrosis factor receptor 2

references

Li Q, Zhang Q, Wang M, Zhao S, Ma J, Luo N, et al. Interferon-gamma and tumor necrosis factor-alpha disrupt epithelial barrier function by altering lipid composition in membrane microdomains of tight junction. Clin Immunol 2008;126:67–80.

Ye D, Ma I, Ma TY. Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol 2006;290:G496–504.

van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129–135.

Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn’s disease. Am J Gastroenterol 2002; 97: 2000–2004.

Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006;130:323–333.

Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005;128:376–392.

Shi Y, Liu HR, Hua WG, Qin XD, Wu HG, Qian JL. Study on the modulating mechanism of colonic TNF-α and IL-10mRNA expression in CD rats with acupuncture and moxibustion. Chin Arch Tradit Chin Med (Chin) 2005;23:272–275.

Shi Y, Wu HG. Clinical research of herbs-partition moxibustion treating Crohn’s disease. Jiangxi J Tradit Chin Med (Chin) 2003;34(8):16–17.

Shi Y, Wu HG, Qin XD, Tan LY, Zhang W, Hua XG, et al. The acupuncture effect on E-selectin and ICAM-1 expression in the colonic mucosa with Crohn’s disease rats. J Jiangxi Univ Tradit Chin Med (Chin) 2005;17:37–39.

Liu HR, Hua XG, Shi Y, Tan LY, Zhang LS. Effects of acupuncture and moxibustion on substance P and neurokinin-1 receptor in Crohn’s disease rats. Acta Univ Tradit Med Sinensis Pharmacol Shanghai (Chin) 2005;19(2): 48–50.

Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989; 96:795–803.

Elson CO. Genes, microbes, and T cells-new therapeutic targets in Crohn’s disease. N Engl J Med 2002;346:614–616.

Shanahan F. Crohn’s disease. Lancet 2002;359:62–69.

Shen L, Su L, Turner JR. Mechanisms and functional implications of intestinal barrier defects. Dig Dis 2009;27:443–449.

Mankertz J, Schulzke JD. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr Opin Gastroenterol 2007;23:379–383.

Troeger H, Richter JF, Beutin L, Günzel D, Dobrindt U, Epple HJ, et al. Escherichia coli alpha-haemolysin induces focal leaks in colonic epithelium: a novel mechanism of bacterial translocation. Cell Microbiol 2007;9:2530–2540

Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995;270:1203–1207.

Bitton A, Dobkin PL, Edwardes MD, Sewitch MJ, Meddings JB, Rawal S, et al. Predicting relapse in Crohn’s disease: a biopsychosocial model. Gut 2008; 57:1386–1392.

Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129:550–564.

Apostolaki M, Armaka M, Victoratos P, Kollias G. Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr Dir Autoimmun 2010;11:1–26.

Hehlgans T, Mannel DN. The TNF-TNF receptor system. Biol Chem 2002;383:1581–1585.

Ma TY, Boivin MA, Ye D, Pedram A, Said HM. Mechanism of TNF-alpha modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol 2005;288:G422–430.

Guy-Grand D, DiSanto JP, Henchoz P, Malassis-Séris M, Vassalli P. Small bowel enteropathy: role of intraepithelial lymphocytes and of cytokines (IL-12, IFN-gamma, TNF) in the induction of epithelial cell death and renewal. Eur J Immunol 1998;28:730–744.

Gitter AH, Bendfeldt K, Schulzke JD, Fromm M. Leaks in the epithelium barrier caused by spontaneous and TNF-alpha-induced single-cell apoptosis. FASEB J 2000;14:1749–1753.

Schulzke JD, Bojarski C, Zeissig S, Heller F, Gitter AH, Fromm M. Disrupted barrier function through epithelial cell apoptosis. Ann N Y Acad Sci 2006;1072:288–299.

von Boyen GB, Steinkamp M, Geerling I, Reinshagen M, Schäfer KH, Adler G, et al. Pro-inflammatory cytokines induce neurotrophic factor expression in enteric glia: a key to the regulation of epithelial apoptosis in Crohn’s disease. Inflamm Bowel Dis 2006;12:346–354.

Schmitz H, Fromm M, Bentzel CJ, Scholz P, Detjen K, Mankertz J, et al. Tumor necrosis factor-alpha (TNF alpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J Cell Sci 1999;112(pt 1):137–146.

Bruewer M, Samarin S, Nusrat A. Inflammatory bowel disease and the apical junctional complex. Ann N Y Acad Sci 2006;1072:242–252.

Clayburgh DR, Shen L, Turner JR. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 2004;84:282–291.

Laukoetter MG, Bruewer M, Nusrat A. Regulation of the intestinal epithelial barrier by the apical junctional complex. Curr Opin Gastroenterol 2006;22:85–89.

Gibson PR. Increased gut permeability in Crohn’s disease: is TNF the link? Gut 2004;53:1724–1725.

Hollander D. Crohn’s disease, TNF-alpha, and the leaky gut: the chicken or the egg? Am J Gastroenterol 2002; 97:1867–1868.

Stallmach A, Giese T, Schmidt C, Ludwig B, Mueller-Molaian I, Meuer SC. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn’s disease. Int J Colorect Dis 2004;19:308–315.

Raddatz D, Bockemuhl M, Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 2005;17:547–557.

Laukoetter MG, Nava P, Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol 2008;14:401–407.

Joos S, Brinkhaus B, Maluche C, Maupai N, Kohnen R, Kraehmer N, et al. Acupuncture and moxibustion in the treatment of active Crohn’s disease: a randomized controlled study. Digestion 2004;69:131–139.

FULL TEXT LINK

More>

浏览量

663

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Effect of two Chinese medicinal compounds, blood-activating and water-draining medicine, on tumor necrosis factor α and nuclear factor κ B expressions in rats with intracerebral hemorrhage

Moxibustion for managing type 2 diabetes mellitus: A systematic review

Review on efficacy and health services research studies of complementary and alternative medicine in inflammatory bowel disease

Effect of acupoint Sanyinjiao (SP6) moxibustion on the first stage of labor and uterine contractive pain in primiparae

The mechanistic studies of acupuncture and moxibustion in Taiwan